BASIL试验:膝下动脉病变患者静脉旁路与普通球囊血管成形术结局比较
BASIL试验亚组分析比较了104例因严重肢体缺血合并膝下动脉病变患者随机接受膝下静脉旁路或普通球囊血管成形术的结局。两组无截肢生存率和总生存率无显著差异,但静脉旁路组静息痛缓解更快,初始住院时间更长。作者认为需BASIL-2和BEST-CLI等进一步随机试验确定首选血运重建方式。
要点
- 膝下静脉旁路与普通球囊血管成形术在无截肢生存率和总生存率上无显著差异。
- 静脉旁路组静息痛缓解显著更快(p=.005),但组织愈合改善无显著差异。
- 静脉旁路组初始住院中位时间显著更长(18 vs. 10天,p<.0001)。
核心结论
- 膝下静脉旁路与普通球囊血管成形术在无截肢生存率和总生存率上无统计学显著差异,但临床趋势倾向静脉旁路优先策略。
- 需BASIL-2和BEST-CLI等进一步随机试验确定适合静脉旁路的严重肢体缺血患者应首选旁路还是腔内干预。
研究设计与样本
- BASIL试验亚组分析,纳入因严重肢体缺血合并膝下动脉病变(伴或不伴股腘动脉病变)随机接受膝下静脉旁路或普通球囊血管成形术的患者。
- 共识别104例膝下动脉病变患者,56例随机至膝下静脉旁路,48例随机至膝下普通球囊血管成形术。
- 主要结局为无截肢生存率,次要结局包括总生存率、30天死亡率和并发症、免于动脉再干预、即刻技术成功、重复和交叉干预、住院时间及血运重建质量。
主要发现
- 两组无截肢生存率和总生存率无统计学显著差异,但临床重要趋势倾向静脉旁路优先策略。
- 静脉旁路组静息痛缓解显著快于普通球囊血管成形术组(p=.005),组织愈合改善无显著差异。
- 初始住院中位时间静脉旁路组显著长于普通球囊血管成形术组(18 vs. 10天,p<.0001)。
- 随机化至主要终点期间中位总住院时间两组无差异(静脉旁路43.5天 vs. 普通球囊血管成形术42天)。
- 基线时静脉旁路组慢性肾脏病和非甾体抗炎药使用更多,普通球囊血管成形术组既往外科动脉干预和抗高血压药使用更多。
临床怎么用
- 对于适合静脉旁路的严重肢体缺血合并膝下动脉病变患者,选择旁路或腔内干预需权衡静息痛缓解速度与住院时间。
- 静脉旁路虽静息痛缓解更快,但初始住院时间更长,临床决策应结合患者具体情况。
- 当前证据尚不足以确定膝下血运重建的首选方式,需等待BASIL-2和BEST-CLI等试验结果。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim was to compare outcomes in a subgroup of patients with infrapopliteal (IP) disease randomised to infrapopliteal vein bypass (VB) or plain balloon angioplasty (PBA) in the original BASIL trial. METHODS: A comparison of outcomes from patients randomised to VB or PBA undergoing revascularisation for severe limb ischaemia (SLI) because of IP disease with or without femoropopliteal disease. Data were extracted from case report forms from the BASIL trial. The primary outcome was amputation free survival (AFS); secondary outcomes included overall survival (OS), 30 day mortality and morbidity, freedom from arterial re-intervention, immediate technical success, repeat and crossover interventions, length of hospital stay, and quality of revascularisation. RESULTS: A total of 104 patients were identified in the BASIL study with IP disease, 56 randomised to IP VB, and 48 to IP PBA. Groups were similar at baseline except for more chronic kidney disease and non-steroidal anti-inflammatory drug use in the VB group, and more previous surgical arterial intervention and antihypertensive use in the PBA group. There were no statistically significant differences in AFS or OS; however, clinically important trends were apparent in favour of a VB first strategy. Patients allocated to VB demonstrated significantly quicker relief of rest pain when compared with PBA (p = .005), but no significant differences in improved tissue healing. Median length of index hospital admission was significantly greater in the VB than in the PBA group (18 vs. 10 days, p < .0001) but there was no difference between the two groups in median total hospital stay between randomisation and the primary endpoint (VB 43.5 vs. PBA 42 days). CONCLUSIONS: Further randomised trials, like BASIL-2 and BEST-CLI, are required to determine whether patients with severe limb ischaemia who require IP revascularisation and who are suitable for VB should have bypass or endovascular intervention as their primary revascularisation procedure.
引用
- Popplewell MA, Davies HOB, Narayanswami J, et al. A Comparison of Outcomes in Patients with Infrapopliteal Disease Randomised to Vein Bypass or Plain Balloon Angioplasty in the Bypass vs. Angioplasty in Severe Ischaemia of the Leg (BASIL) Trial. Eur J Vasc Endovasc Surg. 2017. PMID: 28602580. doi:10.1016/j.ejvs.2017.04.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。